PresVu Eye Drops: Ditch Reading Glasses in Just 15 Minutes

New Delhi: Entod Pharmaceuticals has secured approval from the Drugs Controller General of India (DCGI) for its innovative PresVu eye drops, marking a significant advancement in the treatment of presbyopia. The approval follows a nod from the Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO).

PresVu is the first eye drop in India designed specifically for individuals with presbyopia, a common age-related condition that affects the ability to focus on nearby objects. This condition typically impacts people over the age of 40 and can severely affect daily activities by making it difficult to read without glasses.

Globally, between 1.09 billion and 1.80 billion people are estimated to suffer from presbyopia, signifying the widespread nature of the issue.

Nikkhil K Masurkar, CEO of Entod Pharmaceuticals said, “PresVu has been developed after years of dedicated research and development. The DCGI’s approval is a significant milestone in our mission to revolutionise eye care in India.”

PresVu not only offers a non-invasive alternative to reading glasses but also provides additional benefits, such as lubricating the eyes. The formula features advanced dynamic buffer technology that quickly adapts to the pH of tears, ensuring prolonged effectiveness and protection.

Dr Aditya Sethi highlighted that PresVu enhances near vision within just 15 minutes of application, offering a substantial improvement over traditional methods like reading glasses, contact lenses, or surgery. He added that early detection and consultation are crucial for managing presbyopia effectively.

Commenting on the eye drop’s potential, Dr Dhananjay Bakhle described PresVu as a promising non-invasive solution for presbyopia patients, eliminating the dependency on reading glasses.